updated 6/20/2005 6:37:22 PM ET 2005-06-20T22:37:22

Two generic versions of a major AIDS drug were tentatively approved by the Food and Drug Administration on Monday.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

The agency said it was giving tentative approval to applications for nevirapine tablets manufactured by two companies in India: Ranbaxy Laboratories Limited in Guragon and Aurobindo Pharma Limited in Hyderabad.

These are the first generic versions of Viramune Tablets manufactured by Boehringer Ingelheim.

The new generic versions won’t be immediately available in the United States because of patent exclusivity rules.

But the approval means the generic versions meet the FDA’s standards and can be used by relief organizations outside the United States funded by President Bush’s $15 billion AIDS relief plan.

Nevirapine is in the class of drugs that help keep the AIDS virus from reproducing. It is used in combination with other antiretroviral agents.

The administration was criticized last year for refusing to purchase drugs that hadn’t been reviewed by the FDA. AIDS activists contended it was trying to bolster the sales of U.S. drug makers at the expense of AIDS patients in the developing world.

Research on nevirapine has drawn controversy, and in April an expert scientific panel at the Institute of Medicine concluded that, while U.S. studies on the drug in Africa violated federal patient protection rules, the work was conducted well enough to support its conclusions that the drug could be used safely to protect babies.

The Associated Press reported in December that the U.S. Office of Human Research Protections had concluded the NIH experiment in Uganda that dated to the mid-1990s had violated federal patient safety rules.

© 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments